A brief review: some compounds targeting YAP against malignancies
- 8 May 2019
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 15 (13) , 1535-1543
Abstract
YAP, acting as a crucial transcription factor in nucleus, regulates the organ size, tissue homeostasis and tumorigenesis. Dysregulation of Hippo–YAP pathway brings a significant impact on the occur...Keywords
This publication has 52 references indexed in Scilit:
- Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAPGenes & Development, 2012
- Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancerCancer Chemotherapy and Pharmacology, 2011
- YAP is a candidate oncogene for esophageal squamous cell carcinomaCarcinogenesis, 2010
- Selective inhibition of BET bromodomainsNature, 2010
- YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human diseaseThis paper is one of a selection of papers published in this Special Issue, entitled CSBMCB’s 51st Annual Meeting – Epigenetics and Chromatin Dynamics, and has undergone the Journal’s usual peer review process.Biochemistry and Cell Biology, 2009
- Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth controlGenes & Development, 2007
- Structure and acetyl-lysine recognition of the bromodomainOncogene, 2007
- Novobiocin Induces a Distinct Conformation of Hsp90 and Alters Hsp90−Cochaperone−Client InteractionsBiochemistry, 2004
- salvador Promotes Both Cell Cycle Exit and Apoptosis in Drosophila and Is Mutated in Human Cancer Cell LinesCell, 2002
- Photodynamic therapy with verteporfin: A new treatment in ophthalmologySeminars in Ophthalmology, 2001